Portal, Daniella E.
Weiss, Robert E.
Wojtowicz, Malgorzata
Mansour, Amal
Monken, Claude
Mehnert, Janice M.
Aisner, Joseph A.
Kane, Michael
Nishioka, Jennifer
Aisner, Seena
Peters, Stephen
Stein, Mark N.
Kim, Isaac Y.
Mayer, Tina M.
Shih, Weichung
Gulley, James http://orcid.org/0000-0002-6569-2912
Streicher, Howard
Singer, Eric A.
Lattime, Edmund C.
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U01CA132194, R21CA121589, P30CA072720, U01CA132194)
Article History
Received: 26 March 2019
Revised: 1 June 2019
Accepted: 3 June 2019
First Online: 20 June 2019
Compliance with ethical standards
:
: ECL is an inventor of the patented recombinant vaccinia GM-CSF that has been licensed to Sillajen and is being studied as JX-594 (Pexa-Vec). As such, he derives royalties and licensing fees from the Thomas Jefferson University where the patent is held. EAS receives research funding from Astellas/Medivation. The remaining authors declared no potential conflicts.